Butin

Butin

SCHEMBL5504140

O=C1CC(c2ccc(O)c(O)c2)Oc2cc(O)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 12/20 1.00
TUBB4A P04350 1/20 0.79
TUBB P07437 1/20 0.79
YES1 P07947 1/20 0.79
TUBA3C P0DPH7 1/20 0.79
TUBA1B P68363 1/20 0.79
TUBA4A P68366 1/20 0.79
TUBB4B P68371 1/20 0.79
TUBB3 Q13509 1/20 0.79
TUBB2A Q13885 1/20 0.79
TUBB8 Q3ZCM7 1/20 0.79
TUBA3E Q6PEY2 1/20 0.79
TUBA1A Q71U36 1/20 0.79
ESR2 Q92731 1/20 0.79
TUBA1C Q9BQE3 1/20 0.79
TUBB6 Q9BUF5 1/20 0.79
TUBB2B Q9BVA1 1/20 0.79
TUBB1 Q9H4B7 1/20 0.79
PTPN1 P18031 2/20 0.73
PSMB5 P28074 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butin SCHEMBL29929348 1.00 CYP19A1 (1.00) CYP19A1TUBB4ATUBBYES1TUBA3C
Butin SCHEMBL29929512 1.00 CYP19A1 (1.00) CYP19A1TUBB4ATUBBYES1TUBA3C
Butin SCHEMBL68554 1.00 CYP19A1 (1.00) CYP19A1TUBB4ATUBBYES1TUBA3C
Liquirtigenin SCHEMBL74552 0.88 CYP19A1 (1.00) CYP19A1TUBB4ATUBBYES1TUBA3C
Liquirtigenin SCHEMBL29552383 0.88 CYP19A1 (1.00) CYP19A1TUBB4ATUBBYES1TUBA3C
Liquirtigenin SCHEMBL26970367 0.88 CYP19A1 (1.00) CYP19A1TUBB4ATUBBYES1TUBA3C
Liquirtigenin SCHEMBL30352791 0.88 CYP19A1 (1.00) CYP19A1TUBB4ATUBBYES1TUBA3C
Liquirtigenin SCHEMBL1071066 0.88 CYP19A1 (1.00) CYP19A1TUBB4ATUBBYES1TUBA3C
SCHEMBL15218643 0.88 CYP19A1 (0.79) CYP19A1TUBB4ATUBBYES1TUBA3C
Liquirtigenin SCHEMBL4649862 0.87 CYP19A1 (0.97) CYP19A1TUBB4ATUBBYES1TUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11517603-B2 Bone remodeling accelerator HOKURIKU UNIVERSITY (JP) 2022-12-06 US claimed
US-20200268818-A1 BONE REMODELING ACCELERATOR HOKURIKU UNIVERSITY (JP) 2020-08-27 US claimed
EP-3685836-A1 BONE REMODELING ACCELERATOR Hokuriku University (JP) 2020-07-29 EP claimed
US-20180216152-A1 METHOD FOR THE BIOTECHNOLOGICAL PRODUCTION OF FLAVONE GLYCOSIDE DIHYDROCHALCONES SYMRISE AG (DE) 2018-08-02 US claimed
US-9877946-B2 Method for treating, managing, inhibiting, or preventing obesity Research & Business Foundation Sungkyunkwan University (KR) 2018-01-30 US claimed
EP-2963109-B1 Process for the biotechnological production of flavanonglycoside dihydrochalcones SYMRISE AG (DE) 2017-09-06 EP claimed
US-20170087126-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVER SITY (KR) 2017-03-30 US claimed
US-9549908-B2 Composition for inducing differentiation into beige and brown adipocytes and method of inducing the same Research & Business Foundation Sungkyunkwan University, Ltd. (KR) 2017-01-24 US claimed
WO-2016050656-A1 METHOD FOR THE BIOTECHNOLOGICAL PRODUCTION OF FLAVONOIDS SYMRISE AG (DE) 2016-04-07 WO claimed
EP-3002335-A1 Process for the biotechnological production of flavonoids Symrise AG (DE) 2016-04-06 EP claimed
US-20150374643-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME Research & Business Foundation Sungkyunkwan University (KR) 2015-12-31 US claimed
US-11517603-B2 Bone remodeling accelerator HOKURIKU UNIVERSITY (JP) 2022-12-06 US disclosed
US-20200268818-A1 BONE REMODELING ACCELERATOR HOKURIKU UNIVERSITY (JP) 2020-08-27 US disclosed
US-20200268818-A1 BONE REMODELING ACCELERATOR HOKURIKU UNIVERSITY (JP) 2020-08-27 US disclosed
EP-3685836-A1 BONE REMODELING ACCELERATOR Hokuriku University (JP) 2020-07-29 EP disclosed
WO-2006020164-A1 SKIN CARE COMPOSITION CONTAINING A FLAVONOID AND VITAMIN B3 THE PROCTER & GAMBLE COMPANY (US) 2006-02-23 WO disclosed
US-20060018861-A1 Skin care composition PROCTER & GAMBLE COMPANY, THE 2006-01-26 US disclosed
US-20060018858-A1 Skin care composition THE PROCTER & GAMBLE COMPANY 2006-01-26 US disclosed
US-20060018862-A1 Substrate based skin care device PROCTER & GAMBLE COMPANY, THE 2006-01-26 US disclosed
US-20060018860-A1 Skin care composition PROCTER & GAMBLE COMPANY, THE 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170087126-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME FABP4, PLIN1, PRDM7 CYP19A1 1244/4885TUBB4A 859/4885TUBB 2704/4885
US-11517603-B2 Bone remodeling accelerator SOST, COL2A1, CXCL12 CYP19A1 43/4885TUBB4A 4328/4885TUBB 4771/4885
US-20200268818-A1 BONE REMODELING ACCELERATOR SOST, COL2A1, CXCL12 CYP19A1 43/4885TUBB4A 4328/4885TUBB 4771/4885
US-20150374643-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME FABP4, PLIN1, PRDM7 CYP19A1 1244/4885TUBB4A 859/4885TUBB 2704/4885
US-20060018860-A1 Skin care composition CUTA, C1QBP, FLNB CYP19A1 1611/4885TUBB4A 464/4885TUBB 911/4885
US-20060018862-A1 Substrate based skin care device CUTA, TYR, PROC CYP19A1 357/4885TUBB4A 4224/4885TUBB 4121/4885
US-20060018858-A1 Skin care composition CUTA, FLNB, CYP24A1 CYP19A1 799/4885TUBB4A 359/4885TUBB 806/4885
US-20060018861-A1 Skin care composition CUTA, SERPINB6, FLNB CYP19A1 1092/4885TUBB4A 364/4885TUBB 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.